

## Electronic Supplementary Information

### Metal binding properties of pyrimidinophanes and their acyclic counterparts

Sergey N. Podyachev,<sup>\*a</sup> Vyacheslav E. Semenov,<sup>a</sup> Victor V. Syakaev,<sup>a</sup> Nadezda E. Kashapova,<sup>b</sup>  
Svetlana N. Sudakova,<sup>a</sup> Julia K. Voronina,<sup>a</sup> Anatoly S. Mikhailov,<sup>a</sup> Alexandra D. Voloshina,<sup>a</sup>  
Vladimir S. Reznik,<sup>a</sup> Alexander I. Konovalov<sup>a</sup>

<sup>a</sup> *A. E. Arbuzov Institute of Organic and Physical Chemistry, Kazan Scientific Center of Russian Academy of Sciences, Arbuzov str., 8, 420088, Kazan, Russia*



<sup>b</sup> *Kazan National Research State Technological University, K. Marks str., 68, 420015, Kazan, Russia*

\*Corresponding author. Fax: +07 843 2731872; e-mail: spodyachev@iopc.ru





Contents	S1
The structural formulae of the investigated compounds <b>1-8</b>	S2
Experimental extraction conditions	S3
Experimental procedure of <sup>1</sup> H NMR spectroscopic titrations	S4
<sup>1</sup> H and <sup>15</sup> N NMR chemical shifts of 2-thiocytosine fragments in free ligands and Ag <sup>+</sup> complexes	S4
Geometry of the pyrimidinophane <b>7c</b> in the crystal and the numbering scheme	S5
Determination of the minimal inhibitory concentrations of AgPic and its complexes with pyrimidinic ligands.	S6-S7

## The structural formulae of the investigated compounds 1-8



### Pyrimidine units



### Podands



### Pyrimidinophanes



## Experimental extraction conditions

The  $\text{CHCl}_3$  was saturated with  $\text{H}_2\text{O}$  before the use to prevent volume changes during the extraction. Aqueous metal picrate solutions (5 ml) buffered at 7.3 pH and the solutions of extractant (5 ml,  $2.5 \times 10^{-5}$  to  $1 \times 10^{-3}$  M) in  $\text{CHCl}_3$  were magnetically stirred in a flask. The extraction equilibrium was reached after vigorous stirring for 1.5 h at  $25^\circ\text{C}$ . Then two phases were allowed to settle for 1 h and afterwards separated by centrifugation. The absorbances  $A_1$  of aqueous phase after extraction and  $A_0$  of aqueous phase before extraction were measured at  $\lambda_{\text{max}} = 355$  nm (the wavelength of maximum absorption of the picrate ion). All data were obtained from three independent experiments. The aqueous metal picrate solutions ( $[\text{metal salt}] = 1 \times 10^{-2}$  M;  $[\text{picric acid}] = 2.5 \times 10^{-4}$  M) were prepared by stepwise addition of the  $2.5 \times 10^{-4}$  M aqueous picric acid solution to the calculated amounts of metal salts. The obtained solutions were stirred at pH 7.3 with using tris(hydroxymethyl)aminomethane- $\text{HNO}_3$  (0.05 M) as a buffer. The percent of extraction was calculated as a ratio  $E\% = 100 \times (A_0 - A_1) / A_0 = \alpha \times 100\%$ .  $E\%$  uncertainties are generally  $\leq 2\%$ .

To evaluate the stoichiometry of the complex formation with  $\text{Ag}^+$  the Job's method was applied. Series of isomolar solutions containing various mole amounts of picric acid and ligand (their total concentration  $2.5 \cdot 10^{-4}$  M) and constant amount of metal ions ( $1 \cdot 10^{-2}$  M) were prepared. The obtained solutions were stirred in the buffer with pH 7.3 for 1 h, the water layer was separated and spectrophotometrically measured at  $\lambda_{\text{max}} = 355$  nm. The maximum at the plot dependence of  $\text{AgPic}$  content in organic layer versus its initial mole fraction in water indicates the ratio of the stoichiometry coefficients of  $\text{Ag}^+$  cation and ligand in the complex.

## Experimental procedure of $^1\text{H}$ NMR spectroscopic titrations


A Bruker AVANCE 600 spectrometer was used to measure the  $^1\text{H}$  NMR shifts of the H protons of the receptors. NMR titrations were performed by adding aliquots of the mixture of the ligand (3mmol/l) and silver picrate  $\text{AgPic}\cdot\text{H}_2\text{O}$  (12 mmol/l) o the solution of ligand (3 mmol/l) directly in the NMR tube. NMR  $^1\text{H}$  spectra were recorded at every step of addition. The stability constants ( $\log\beta$ ) were determined by the direct analysis of the molar  $^1\text{H}$  NMR titration curves using the DynaFit software [S1].

S1. P.Kuzmic, *Anal. Biochem.*, 1996, **237**, 260.

## $^1\text{H}$ and $^{15}\text{N}$ NMR chemical shifts of 2-thiocytosine fragments in free ligands and $\text{Ag}^+$ complexes

**Table S1.**


$^1\text{H}$  and  $^{15}\text{N}$  NMR chemical shifts ( $\delta$ , ppm) of thiocytosine fragments in free ligands and  $\text{Ag}^+$  complexes in  $\text{CDCl}_3/\text{DMSO}-d_6 = 1:1$  (v/v) ( $\text{CD}_3\text{OD}/\text{DMSO}-d_6 = 1:1$  (v/v)) at 303 K.

Compound	Chemical shift, $\delta$ ppm							
	S- $\text{CH}_n$	Ar- $\text{H}(5)$	Ar- $\text{CH}_3$	N(4)- $\text{CH}_n$	N(4) $\text{H}$	$\text{N}(1)$	$\text{N}(3)$	$\text{N}(4)$
								
<b>1</b>	2.39	6.02	2.17	3.02	-	244	(-) <sup>a</sup>	65
<b>1+Ag<sup>+</sup></b>	2.50	6.25	2.35	3.10	-	213	(-) <sup>a</sup>	(-) <sup>a</sup>
<b>3</b>	2.36	5.89	2.10	3.24	6.88	243	(-) <sup>a</sup>	86
<b>3+Ag<sup>+</sup></b>	2.43	6.05	2.23	3.34	7.71	210	(-) <sup>a</sup>	96
<b>4b</b>	2.99	6.03	2.17	3.02	-	243	228	65
	(2.71)	(5.66)	1.83	2.71	-			
<b>4b+Ag<sup>+</sup></b>	3.11	6.32	2.37	3.13	-	210	210	(-) <sup>a</sup>
	(2.83)	(5.92)	(2.03)	(2.78)				
<b>7a</b>	2.95	5.90	2.10	3.32	6.96	(-) <sup>b</sup>	(-) <sup>b</sup>	(-) <sup>b</sup>
<b>7a+Ag<sup>+</sup></b>	3.04	6.04	2.22	3.46	7.56	(-) <sup>b</sup>	(-) <sup>b</sup>	(-) <sup>b</sup>
<b>7b</b>	2.94	5.89	2.09	3.27	6.93	(-) <sup>b</sup>	(-) <sup>b</sup>	(-) <sup>b</sup>
<b>7b+Ag<sup>+</sup></b>	3.34	6.05	2.23	3.03	7.67	(-) <sup>b</sup>	(-) <sup>b</sup>	(-) <sup>b</sup>
<b>7c</b>	2.94	5.88	2.08	3.23	6.93	(-) <sup>b</sup>	(-) <sup>b</sup>	(-) <sup>b</sup>
<b>7c+Ag<sup>+</sup></b>	3.01	6.04	2.20	3.31	7.58	(-) <sup>b</sup>	(-) <sup>b</sup>	(-) <sup>b</sup>

<sup>a</sup> No signals for some nuclei were obtained

<sup>b</sup> No experimental data were obtained

### Geometry of the pyrimidinophane 7c in the crystal and the numbering scheme



## **Determination of the minimal inhibitory concentrations of AgPic and its complexes with pyrimidinic ligands.**

The in vitro antibacterial and antifungal activity of the synthesized compounds were investigated against *Pseudomonas aeruginosa* 9027, *Escherichia coli* F-50, *Staphylococcus aureus* 209p, *Bacillus subtilis* 6633 and yeast *Candida Albicans* 885-653. The antibacterial and antifungal assays were performed in nutrient broth (bacteria  $3 \times 10^5$  cfu/mL) and Sabouraud dextrose broth (fungi  $2 \times 10^{3-4}$  cfu/mL). Positive growth control and standard drug controls were also run simultaneously. The MICs were defined as the lowest concentrations that showed no growth and recorded by visual observation in every 24 h during 5 days for bacteria and after incubation during 14 days for fungi.

The bactericidal and fungicidal activity was determined as follows. Assay tubes were filled with 1 mL of test compound solution in nutrient agar. Concentrations of test compounds were varied from 12.5 to  $10^4$   $\mu\text{g/mL}$ . Normal saline broth (bacteria  $3 \times 10^5$  cfu/mL), 1 mL was added to the tubes and for 5 min, 10 min, 15 min, 30 min, 1 h, 1.5 h, 2 h, 4 h the inocula were prepared by transferring the broth onto petri plates containing meal-peptone agar. Petri plates were incubated at 37°C and minimum bactericidal concentration (MBC) recorded as the test compound dilution affecting total cell death. For fungicidal activity determination the tubes with the test compounds and fungi were incubated at 26°C. For 10 min, 20 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 6 h the inocula were prepared in Sabouraud dextrose broth and incubated at 26°C.

Results are presented in Table S2.

**Table S2.** *In vitro* antibacterial and antifungal activity AgPic and complexes of the salt with acyclic and macrocyclic pyrimidines<sup>a</sup>

Complexes	<i>Sa</i>	<i>Ba</i>	<i>Ec</i>	<i>Pa</i>	<i>Ca</i>
Minimal Bacteriostatic and Fungistatic Concentrations, µg/mL					
AgPic	3.9	31.3	7.8	15.6	31.3
<b>Ag·L<sub>4b</sub>·Pic</b>	31.3	62.5	125	500	62.5
<b>Ag·2L<sub>1</sub>·Pic</b>	31.3	62.5	125	500	62.5
<b>Ag·L<sub>3</sub>·Pic</b>	15.6	62.5	125	500	250
<b>Ag·L<sub>7a</sub>·Pic</b>	15.6	62.5	125	500	250
Minimal Bactericidal and Fungicidal Concentrations, µg/mL					
AgPic	>500	>500	>500	>500	>500
<b>Ag·L<sub>4b</sub>·Pic</b>	>500	>500	>500	>500	>500
<b>Ag·2L<sub>1</sub>·Pic</b>	>500	>500	>500	>500	>500
<b>Ag·L<sub>3</sub>·Pic</b>	>500	>500	>500	>500	>500
<b>Ag·L<sub>7a</sub>·Pic</b>	>500	>500	>500	>500	>500

<sup>a</sup> The tests were performed in duplicate and repeated twice; Pa, *Pseudomonas aeruginosa*; Ec, *Escherichia coli*; Sa, *Staphylococcus aureus*; Ba, *Bacillus subtilis*; Ca, *Candida Albicans*.

Minimal bacteriostatic concentrations (MBC) of the salt against bacteria *Staphylococcus aureus*, *Bacillus subtilis*, *Escherichia coli* have values of 3.9, 31.3 and 7.8 µg/mL, respectively, minimal fungistatic concentrations (MFC)